ReNeuron Group plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RNUGF research report →
Companywww.reneuron.com
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells.
- CEO
- Iain Gladstone Ross
- IPO
- 2007
- Employees
- 26
- HQ
- Pencoed, GB
Price Chart
Valuation
- Market Cap
- $62.89K
- P/E
- -0.01
- P/S
- 0.09
- P/B
- 0.01
- EV/EBITDA
- 0.89
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -742.08%
- Op Margin
- -1342.45%
- Net Margin
- -1020.38%
- ROE
- -72.37%
- ROIC
- -105.51%
Growth & Income
- Revenue
- $530.00K · 31.51%
- Net Income
- $-5,408,000 · 44.18%
- EPS
- $-0.09 · 44.29%
- Op Income
- $-7,115,000
- FCF YoY
- 0.12%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.03
- Avg Volume
- 278.072
Get TickerSpark's AI analysis on RNUGF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our RNUGF Coverage
We haven't published any research on RNUGF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RNUGF Report →